Scaling-down biopharmaceutical production processes via a single multi-compartment bioreactor (SMCB)

Biopharmaceutical production processes often use mammalian cells in bioreactors larger than 10,000 L, where gradients of shear stress, substrate, dissolved oxygen and carbon dioxide, and pH are likely to occur. As former tissue cells, producer cell lines such as Chinese hamster ovary (CHO) cells sensitively respond to these mixing heterogeneities, resulting in related scenarios being mimicked in scale-down reactors. However, commonly applied multi-compartment approaches comprising multiple reactors impose a biasing shear stress caused by pumping. The latter can be prevented using the single multi-compartment bioreactor (SMCB) presented here. The exchange area provided by a disc mounted between the upper and lower compartments in a stirred bioreactor was found to be an essential design parameter. Mimicking the mixing power input at a large scale on a small scale allowed the installation of similar mixing times in the SMCB. The particularities of the disc geometry may also be considered, finally leading to a converged decision tree. The work flow identifies a sharply contoured operational field comprising disc designs and power input to install the same mixing times on a large scale in the SMCB without the additional shear stress caused by pumping. The design principle holds true for both nongassed and gassed systems.

Subjects

cell culture

compartment discs

mixing times

multi-compartment system

scale-down

DDC Class

570: Biowissenschaften, Biologie

Funding(s)

SPP 2170: Teilprojekt Experimentelle Multiskalenanalyse und Simulation von 'lifelines' in Bioreaktoren um deren Einfluss auf die Kultivierung von Chinese Hamster Ovary (CHO) Zellen zu untersuchen

Publication version

publishedVersion

Lizenz

https://creativecommons.org/licenses/by/4.0/

Name

Engineering in Life Sciences - 2022 - Gaugler - Scaling‐down biopharmaceutical production processes via a single.pdf

Size

2.93 MB

Format

Adobe PDF

Options

Scaling-down biopharmaceutical production processes via a single multi-compartment bioreactor (SMCB)